MCID: EYD001
MIFTS: 32

Eye Degenerative Disease

Categories: Neuronal diseases, Eye diseases

Aliases & Classifications for Eye Degenerative Disease

MalaCards integrated aliases for Eye Degenerative Disease:

Name: Eye Degenerative Disease 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:9799
ICD10 33 H44.30 H44.5
UMLS 69 C0154777

Summaries for Eye Degenerative Disease

MalaCards based summary : Eye Degenerative Disease is related to cone-rod dystrophy 6 and plantar nerve lesion. An important gene associated with Eye Degenerative Disease is KCNJ13 (Potassium Voltage-Gated Channel Subfamily J Member 13), and among its related pathways/superpathways are Metabolism of fat-soluble vitamins and Proteoglycans in cancer. The drugs Ranibizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotypes are digestive/alimentary and vision/eye

Related Diseases for Eye Degenerative Disease

Graphical network of the top 20 diseases related to Eye Degenerative Disease:



Diseases related to Eye Degenerative Disease

Symptoms & Phenotypes for Eye Degenerative Disease

MGI Mouse Phenotypes related to Eye Degenerative Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 COL2A1 FZD4 GJD2 KCNJ13 LUM VEGFA
2 vision/eye MP:0005391 9.23 COL2A1 CYP4V2 FZD4 GJD2 GUCA1A GUCY2D

Drugs & Therapeutics for Eye Degenerative Disease

Drugs for Eye Degenerative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 347396-82-1 459903
2
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
3
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-02-2 5743
5
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
6
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
8
Menthol Approved Phase 4 2216-51-5 16666
9
Copper Approved Phase 4 7440-50-8 27099
10
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
11
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
12
Ephedrine Approved Phase 4,Phase 2,Phase 1 299-42-3 9294
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Pseudoephedrine Approved Phase 4,Phase 2,Phase 1 90-82-4 7028
15
Temazepam Approved Phase 4 846-50-4 5391
16
Difluprednate Approved Phase 4 23674-86-4 443936
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
19
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
20
Acetylcholine Approved Phase 4 51-84-3 187
21
Theobromine Approved Phase 4 83-67-0 5429
22
Nepafenac Approved Phase 4 78281-72-8 151075
23 Tocopherol Approved, Nutraceutical Phase 4,Phase 3,Phase 1
24
Vitamin C Approved, Nutraceutical Phase 4,Phase 3 50-81-7 5785 54670067
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1 59-02-9 14985
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 11103-57-4, 68-26-8 445354
28
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
29 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Endothelial Growth Factors Phase 4,Phase 2,Phase 3,Phase 1
34 Mitogens Phase 4,Phase 2,Phase 3,Phase 1
35 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
36 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
37 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Tocopherols Phase 4,Phase 3,Phase 1
39 Tocotrienols Phase 4,Phase 3,Phase 1
40 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
41 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Tetrahydrozoline Phase 4,Phase 2,Phase 3,Phase 1
49 Antiemetics Phase 4,Phase 2,Phase 1
50 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 857)

id Name Status NCT ID Phase Drugs
1 Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Unknown status NCT01961414 Phase 4 Aflibercept
2 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
3 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
4 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
5 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
6 Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed NCT01986907 Phase 4 ranibizumab
7 Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment Completed NCT00680498 Phase 4 Ranibizumab;Ranibizumab plus Photodynamic therapy
8 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed NCT02161575 Phase 4 Ranibizumab
9 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
10 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept Completed NCT02125864 Phase 4 Aflibercept
11 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
12 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
13 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
14 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
15 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
16 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
17 A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) Completed NCT01542866 Phase 4
18 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
19 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
20 Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
21 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
22 Study for Recalcitrant Age Related Macular Degeneration Completed NCT01543568 Phase 4 aflibercept 2.0 mg
23 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
24 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
25 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
26 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) Completed NCT01988662 Phase 4
27 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
28 Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4 Ranibizumab;Ranibizumab
29 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4 Eylea
30 Combined Therapy in Age-Related Macular Degeneration (ARMD) Completed NCT00805649 Phase 4 dexamethasone;bevacizumab;triamcincolone
31 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
32 Study EvAluating Genotypes While Using Lucentis 2 Completed NCT01464723 Phase 4 Ranibizumab
33 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
34 Size Progression of Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
35 Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Completed NCT01722656 Phase 4 Aflibercept
36 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
37 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
38 Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
39 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
40 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
41 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
42 Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration Completed NCT00556348 Phase 4 bevacizumab
43 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4 Ranibizumab
44 Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%
45 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4 Verteporfin Photodynamic Therapy;Ranibizumab
46 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
47 Ranibizumab Plus Indomethacin Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
48 VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) Completed NCT00727753 Phase 4 Ranibizumab;Bevacizumab
49 Botulinum Toxin to Improve Lower Blepharoplasty Scar Recruiting NCT02786550 Phase 4 Botulinum Toxin
50 An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen Recruiting NCT03117634 Phase 4 Treat and Extend with Aflibercept 2mg;Fixed Dosing with Aflibercept 2mg

Search NIH Clinical Center for Eye Degenerative Disease

Genetic Tests for Eye Degenerative Disease

Anatomical Context for Eye Degenerative Disease

MalaCards organs/tissues related to Eye Degenerative Disease:

39
Eye, Endothelial, Testes, Retina, Bone, Brain, Skin

Publications for Eye Degenerative Disease

Variations for Eye Degenerative Disease

Expression for Eye Degenerative Disease

Search GEO for disease gene expression data for Eye Degenerative Disease.

Pathways for Eye Degenerative Disease

Pathways related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.46 CYP4V2 GUCA1A GUCY2D
2 11.11 FZD4 LUM VEGFA
3 10.97 COL2A1 VEGFA

GO Terms for Eye Degenerative Disease

Cellular components related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.13 COL2A1 LUM VEGFA
2 photoreceptor disc membrane GO:0097381 8.62 GUCA1A GUCY2D

Biological processes related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.32 FZD4 VEGFA
2 heart morphogenesis GO:0003007 9.26 COL2A1 VEGFA
3 collagen fibril organization GO:0030199 9.16 COL2A1 LUM
4 visual perception GO:0007601 9.1 COL2A1 CYP4V2 GJD2 GUCA1A GUCY2D LUM
5 regulation of rhodopsin mediated signaling pathway GO:0022400 8.96 GUCA1A GUCY2D

Molecular functions related to Eye Degenerative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.62 COL2A1 LUM

Sources for Eye Degenerative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....